This Week’s Cannabis and Hemp
Stocks Added; $DVA.V; $SVSN
Other New Marijuana/Hemp Stocks: ASX: ZLD, BOT, CPH, MDC
Point Roberts, WA, Delta BC – April 21, 2017 –
Investorideas.com, a global news source and investor resource covering actively
traded sectors announces this week’s additions to its cannabis /hemp stock directory for investors
following the sector.
Australian listed (ASX) stocks are at the forefront
of this week’s additions with 4 new stocks being added that include a company
involved in medical cannabis for treatment of a variety of ailments; a cannabis-based
medicine for oncology; cannabidiol treatment for psoriasis and atopic dermatitis and Creso Pharma Limited
(ASX:CPH.AX) a leader in cannabidiol (CBD) innovation, currently developing
cannabis and hemp‐derived therapeutic‐grade Nutraceuticals and Medical Cannabis
products with a broad range of applications in both human and animal health.
Also new this week are Delivra Corp. (TSX:DVA.V) is a specialty biotechnology company who
recently completed a strategic
partnership with Dosecann Inc. and ARA-Avanti RX Analytics Inc. to develop a
unique suite of standardized and commercialized products for the medical
cannabis market and Stereo Vision Entertainment, Inc. (OTC:SVSN) a
media company who is also the majority owner of medical cannabis and organic
hemp subsidiary, MediCannaVision Inc., dba CannaVision.
Investorideas.com cannabis/marijuana and hemp
content now includes: http://cannabisstocknews.blogspot.com on
Blogger.com: the Investorideas.com news and stock directory pages, a cannabis
investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Botanix Pharmaceuticals Ltd. (ASX:BOT.AX) mission is to improve the lives of patients battling acne, psoriasis
and atopic dermatitis, by providing new treatment options for conditions that
currently are inadequately addressed or are treated with therapeutics that are
burdened with side effects profiles. We are harnessing the untapped potential
of a synthetic active pharmaceutical ingredient known as cannabidiol which is
currently being studied for the treatment of epilepsy, pain, arthritis and
schizophrenia amongst other indications. Botanix is preparing for the first
human trials utilizing synthetic cannabidiol in a proprietary drug delivery
system (Permetrex™) for direct skin delivery of the therapy.
Creso
Pharma Limited (ASX:CPH.AX) pharmaceutical expertise and methodological rigour to the world of
medical cannabis and strives for the highest quality in its products,
leveraging science and research in order to develop, register and commercialise
innovative therapeutic approaches targeting the endocannabinoid system. Creso
Pharma is a leader in cannabidiol (CBD) innovation, developing cannabis- and
hemp‐derived therapeutic‐grade Nutraceuticals and Medical Cannabis products with a broad range of
applications in both human and animal health. Creso Pharma’s innovative CBD
fully plant-based nutraceutical products are non-psychoactive, as they contain
only trace amounts of THC. Focusing on unique and innovative product delivery
systems, Creso Pharma is developing therapeutic products and nutraceuticals
manufactured according to the highest GMP standards, and maintaining the
highest levels of compliance across the supply chain. Creso Pharma holds
worldwide rights for a number of proprietary innovative delivery technologies
which enhance the bioavailability and absorption of cannabinoids. Furthermore,
Creso Pharma’s standardised dosage forms are specifically designed and adapted
for human health and for animal health, and for several medical conditions
including pain and anxiety disorders, metabolic disorders and inflammatory
disorders.
Delivra
Corp. (TSX:DVA.V) is a specialty biotechnology company that has a proprietary
transdermal delivery system platform that can shuttle pharmaceutical and
natural molecules, through the skin, in a targeted specific manner. Delivra
manufactures and sells a growing line of natural topical creams with the
proprietary transdermal delivery system platform under the LivRelief™ brand,
for conditions such as joint and muscle pain, nerve pain, varicose veins, wound
healing, and under the LivSport™ brand for sports performance. LivRelief™
products are available in pharmacies, grocery chains, and independent health
food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain
and nerve pain products are also available in the United States on Amazon and
at www.livrelief.com/us. In parallel with its consumer products business,
Delivra also has a mandate to license its patent-pending proprietary
transdermal delivery technology platform to pharmaceutical companies globally,
for the repurposing of pharmaceutical molecules transdermally to treat a broad
range of conditions, along with licensing its over-the-counter products
globally. Delivra is headquartered in Burlington, Ontario and has a research
and development laboratory in Charlottetown, PEI. Cannabis: Completed a strategic partnership with Dosecann Inc. and ARA-Avanti RX
Analytics Inc. to develop a unique suite of standardized and commercialized
products for the medical cannabis market
Medlab
Clinical Ltd. (ASX:MDC.AX) l is an Australian based medical life science
company, with a certified biologics facility in Sydney and sales arms in
Australia and California. Medlab’s research relates to five health areas -
obesity, chronic kidney disease, depression, ageing and muscular skeletal
health and pain management. A lot of Medlab’s research is on the role bacteria
in the gastrointestinal tract play in health and disease, leading to drug
discovery and development of new medicines involving bacteria (pharmacobiotics)
as well as nutritional products. Medlab is also about to commence a human trial
of a cannabis-based medicine for oncology patients with intractable pain,
utilising its small particle medicine delivery system, Nanocelle™. Medlab has a
growing patent portfolio, multiple published research papers and conference
presentations and the Pharmacobiotic trademark – a therapeutic term referring
to both probiotics and biologics.
Stereo
Vision Entertainment, Inc. (OTC:SVSN) is a publicly traded Nevada company focused on creating, acquiring,
and producing multimedia content with its media subsidiaries the majority owned
family entertainment company Inspirational Vision Media and the wholly
owned 9 time Emmy Award winning production company REZN8, and the
majority owned medical cannabis and organic hemp subsidiary, MediCannaVision
Inc., dba CannaVision.
Zelda Therapeutics Limited (ASX:ZLD.AX) has been formed to bring together some of the world’s leading
researchers and clinicians active in the study and use of medicinal cannabis to
treat a variety of ailments.
The complete marijuana/hemp stock list available for purchase in a PDF
format:
Investorideas.com tracks companies in high profile
trading sectors and makes ongoing additions to its stock directories for each
sector. Listing for the stock directories include companies on the
TSX, OTC, NYSE, NASDAQ and global stock exchanges.
Investorideas.com global stock directories are part
of the membership program on the site, accessed either by login and password or
available in PDF format. The directories include stocks trading on the
TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving
retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Ideas
Investorideas.com
is a meeting place for global investors, featuring news, stock directories,
video, podcasts, company profiles, interviews and more in leading sectors.
Sectors we cover include
tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water
stocks, marijuana and hemp stocks, food and beverage (including organic and
LOHAS, wine), defense and security (including biometrics), Latin America,
sports, entertainment, luxury brands and gaming.
The Investorideas.com
content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence
(AI) websites on the Grid and the Waternewswire.com, all featuring
Investorideas.com news and content.
Services for Publicly traded and private companies: http://www.investorideas.com/Investors/Services.asp
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution,social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment